Abstract | PURPOSE: MATERIALS AND METHODS: In this parallel-arm, prospective, multicentre, single-blind study, men who were ≥ 40 years old, had an International Prostate Symptom Score (IPSS) of ≥ 8, an Overactive Bladder Symptom Score (OABSS) of ≥ 3 and an OABSS urgency item score of ≥ 2 were randomised in a 1 : 1 :1 ratio to receive alfuzosin 10 mg alone (Group A) or with propiverine 10 mg (Group B) or 20 mg (Group C) for 8 weeks. Four and 8 weeks after commencing treatment, OABSS was measured along with IPSS, maximal urinary flow rate (Qmax ) and postvoid residual volume (PVR). Adverse events were recorded. RESULTS: A total of 135 men, including 43 in Group A, 48 in Group B and 44 in Group C, completed the study. Relative to baseline, all groups demonstrated significant reductions in OABSS and the IPSS after eight treatment weeks (p < 0.005). The improvement of OABSS in Group C was significantly greater than Group A and B (Group A: 0.70 ± 1.94; Group B: 2.50 ± 2.98; Group C: 4.30 ± 3.40; p < 0.005). An observed improvement of Qmax and PVR in the three groups did not achieve statistical significance. Overall adverse event rates were higher in Group C but not significant compared with others. CONCLUSION:
|
Authors | H J Cho, S C Shin, D Y Seo, J M Cho, J Y Kang, T K Yoo, J H Yu, L H Sung, H S Moon |
Journal | International journal of clinical practice
(Int J Clin Pract)
Vol. 68
Issue 4
Pg. 471-7
(Apr 2014)
ISSN: 1742-1241 [Electronic] India |
PMID | 24471868
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 John Wiley & Sons Ltd. |
Chemical References |
- Benzilates
- Quinazolines
- Urological Agents
- propiverine
- alfuzosin
|
Topics |
- Benzilates
(administration & dosage, adverse effects, therapeutic use)
- Drug Therapy, Combination
- Humans
- Lower Urinary Tract Symptoms
(drug therapy)
- Male
- Middle Aged
- Prospective Studies
- Quinazolines
(administration & dosage, adverse effects, therapeutic use)
- Single-Blind Method
- Treatment Outcome
- Urinary Bladder, Overactive
(drug therapy)
- Urological Agents
(administration & dosage, adverse effects, therapeutic use)
|